Melanoma kills primarily by spreading from the skin to vital organs, where growing tumor deposits disrupt normal function until one or more organs fail. The most frequent lethal pathway, confirmed across decades of autopsy data, is respiratory failure from massive lung involvement, followed closely by complications of brain metastases such as hemorrhage and rising pressure inside the skull.1The American Journal of Surgery. Metastatic pattern of malignant melanoma: A study of 216 autopsy cases But the full picture is more varied and, in some ways, more insidious than a single organ shutting down. Melanoma can infiltrate the liver, heart, intestines, bone, and the membranes lining the brain, and it can trigger deadly complications like blood clots, overwhelming infection, and a wasting syndrome that erodes the body from the inside out.
How Melanoma Leaves the Skin
A melanoma confined to the top layers of the skin is almost always curable with surgery alone. The danger begins when tumor cells break through deeper tissue and gain access to the lymphatic system or the bloodstream. Thicker tumors, measured by how far they extend below the skin surface, are far more likely to reach nearby lymph nodes. When tumor cells invade the tiny lymphatic vessels around the primary melanoma, the likelihood of spreading to multiple sentinel lymph nodes increases, a pattern associated with deeper tumors and the presence of lymphovascular invasion.2PubMed. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma Once cells reach the lymph nodes, they have a gateway to enter the general circulation and seed distant organs.
What makes melanoma especially dangerous compared to many other cancers is its ability to metastasize almost anywhere. Most solid tumors favor one or two distant sites. Melanoma, by contrast, can show up in the lungs, brain, liver, bone, intestines, skin far from the original tumor, adrenal glands, and even the heart. That unpredictability is part of what makes advanced melanoma so difficult to manage.
Respiratory Failure From Lung Metastases
The lungs are the single most common site of fatal melanoma spread. In a classic autopsy study of 216 patients who died from melanoma, the leading cause of death was respiratory failure driven by massive tumor infiltration of the lung tissue and the membranes surrounding the lungs.1The American Journal of Surgery. Metastatic pattern of malignant melanoma: A study of 216 autopsy cases The mechanism is straightforward: as tumor nodules multiply throughout the lungs, they crowd out the healthy tissue that performs gas exchange. The lungs gradually lose the ability to deliver enough oxygen to the blood or to clear carbon dioxide.
In some cases, lung involvement can escalate with alarming speed. Melanoma cells can infiltrate lung tissue and airways in a pattern that closely mimics acute respiratory distress syndrome, the same kind of catastrophic lung failure seen in severe pneumonia or sepsis.3PubMed Central. Acute respiratory failure mimicking acute respiratory distress syndrome due to parenchymal infiltration by metastatic melanoma In these rapidly progressive cases, a patient can go from feeling relatively normal to being unable to breathe adequately in a matter of days. Melanoma can also cause malignant pleural effusions, where fluid accumulates between the lung and the chest wall, compressing the lung and further impairing breathing. These effusions can recur stubbornly even after drainage and sometimes require surgical intervention to manage.4PubMed Central. Pleural Metastatic Melanoma With Recurrent Malignant Pleural Effusions
Brain Metastases and Rising Intracranial Pressure
The brain is the second most common lethal site. Melanoma has a well-known affinity for brain tissue, and brain metastases are found in a strikingly high proportion of patients who die from the disease. Unlike an organ like the liver, the brain sits inside a rigid skull, so there is almost no room for expansion when tumors grow. The result is a dangerous rise in pressure inside the skull.
A study analyzing how patients with brain metastases actually die found that the majority of central nervous system deaths were driven by increasing tumor burden that caused a global decline in brain function. Smaller but still substantial fractions died from focal neurological deficits, acute spikes in intracranial pressure, and treatment-resistant seizures.5PubMed. Causes of Death in Patients With Brain Metastases Melanoma brain metastases are also prone to bleeding, which can cause sudden, stroke-like deterioration. A hemorrhage inside a brain tumor deposit can be the event that tips a patient from stable to critical in hours.
An especially grim scenario is leptomeningeal disease, where melanoma cells spread to the thin membranes and cerebrospinal fluid surrounding the brain and spinal cord. This form of spread causes a constellation of neurological symptoms that rarely improve with treatment, and the median survival after diagnosis has been estimated at roughly two to two and a half months.6ScienceDirect / ESMO Open. How we treat patients with leptomeningeal metastases Because the cancer is bathed in the same fluid that nourishes the nervous system, it can affect multiple areas simultaneously, causing headaches, vision changes, weakness, confusion, and difficulty walking.
Liver Failure
The liver is a major filter for the blood, which makes it a frequent landing zone for circulating tumor cells. When melanoma metastasizes extensively to the liver, it can gradually replace healthy liver tissue with tumor deposits. As functional liver tissue diminishes, the organ loses its ability to process toxins, produce clotting factors, and regulate metabolism. The end stage is liver insufficiency, which can cascade into multiorgan failure.7PubMed. Isolated hepatic perfusion for liver metastases of malignant melanoma
Research has begun to identify molecular links between brain and liver metastases in melanoma. A recent study found evidence of a brain-liver metastasis axis, where circulating tumor cells associated with brain metastases carry a gene signature linked to secondary spread to the liver.8PubMed Central. A Melanoma Brain Metastasis CTC Signature and CTC:B-cell Clusters Associate with Secondary Liver Metastasis: A Melanoma Brain-Liver Metastasis Axis In other words, melanoma cells that have already colonized one organ seem to be molecularly equipped to colonize another, compounding the danger.
Less Obvious Targets That Can Be Lethal
The Heart
Melanoma is one of the cancers most likely to metastasize to the heart, yet cardiac involvement is rarely caught during life because it often causes no symptoms until it triggers a crisis. Autopsy studies indicate that melanoma involves the heart or the sac surrounding it (the pericardium) in more than half of patients with advanced disease.9PubMed Central. Cardiac metastases of melanoma as first manifestation of the disease When symptoms do appear, they tend to come in the form of arrhythmias, heart failure, or fluid buildup around the heart (pericardial effusion) that can compress the organ and impair its pumping.10PubMed Central. Metastatic melanoma of the heart: Retrospective cohort study and systematic review of prevalence, clinical characteristics, and outcomes A large pericardial effusion that develops rapidly can cause cardiac tamponade, a life-threatening emergency where the heart cannot fill properly.
The Gastrointestinal Tract
Melanoma has a peculiar tendency to spread to the small intestine, a pattern not commonly seen with other cancers. These deposits are typically silent in their early stages and are often discovered only when they cause an acute emergency such as bowel obstruction, perforation, or hemorrhage.11PubMed Central. Distant melanoma causing small bowel obstruction A perforation of the bowel wall allows intestinal contents to leak into the abdominal cavity, causing peritonitis and sepsis. Case reports describe patients with known metastatic melanoma presenting to emergency departments with bowel obstruction symptoms, where imaging reveals a perforated segment of intestine.12Medical Science and Discovery. Malignant Melanoma Metastasis as a Cause of Small-Bowel Perforation These surgical emergencies carry high mortality, particularly in patients whose immune systems are already compromised by advanced cancer or its treatment.
Bone and Calcium Complications
Bone metastases from melanoma can cause pain, fractures, and spinal cord compression, but they can also trigger a less obvious and potentially deadly problem: hypercalcemia. When tumor deposits destroy bone tissue, calcium floods the bloodstream. The mechanism involves both direct bone destruction and the release of chemical signals that activate the cells responsible for breaking down bone.13PubMed Central. Malignant melanoma with indiscoverable skin manifestations presenting with paresis and refractory hypercalcemia: A case report Severely elevated calcium disrupts heart rhythm, causes confusion, impairs kidney function, and can be fatal if it resists treatment.
Blood Clots and Pulmonary Embolism
Advanced melanoma substantially increases the risk of blood clots, and these clots can kill independently of the tumor burden in any particular organ. In one study of patients with stage IV melanoma, about a quarter developed venous blood clots, and half of those clots were accompanied by pulmonary embolism, where a clot travels to the lungs and blocks blood flow.14PubMed. High prevalence and risk factors of thromboembolism in stage IV melanoma A separate imaging study found pulmonary embolism in about 6% of melanoma patients undergoing routine staging scans, and nearly three-quarters of those cases were incidental findings, meaning the patient had no obvious symptoms.15Clinical Imaging. High incidence of incidental pulmonary embolism in malignant melanoma staging computed tomography The presence of clots was linked to higher tumor stage, the presence of visceral or brain metastases, and increased mortality.
Modern immunotherapy drugs, which have transformed melanoma treatment, add another layer to this risk. Among melanoma patients treated with immune checkpoint inhibitors, roughly one in five experienced a blood clot event within the follow-up period. The cumulative incidence of clots climbed over time, and patients who developed clots without brain metastases had significantly worse overall survival than those who did not.16Journal for ImmunoTherapy of Cancer. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival The combination of cancer biology, immobility during illness, and the inflammatory effects of treatment all converge to make clotting a persistent and underappreciated threat.
Cachexia and the Wasting Syndrome
Many people assume cancer kills only through the direct destruction of an organ, but melanoma (like other advanced cancers) can kill through a systemic wasting syndrome called cachexia. Patients with cachexia lose muscle mass, fat, and strength even when they are eating, because the cancer disrupts normal metabolic signaling throughout the body. In a mouse model of melanoma-induced cachexia, the heart and skeletal muscle were the first tissues to waste, and the brain showed functional impairment even though it did not lose mass. Secreted factors from both the tumor and the host’s own tissues drove these changes, and an enzyme involved in blood-pressure regulation was identified as a top category of cancer-driven gene changes in host tissue.17PubMed Central. Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice
Cachexia is relevant to mortality because it weakens the heart, impairs breathing muscles, suppresses the immune system, and makes patients more vulnerable to infection and less able to tolerate treatment. In the immunotherapy era, the most common recorded cause of death for advanced melanoma patients is “progressive failure to thrive,” a clinical term that captures the downward spiral of cachexia: loss of appetite, fatigue, weakness, and organ dysfunction that may not be traceable to any single metastatic deposit.18PubMed Central. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Infection and Sepsis
Advanced melanoma erodes the immune system’s ability to fight off ordinary infections, and the treatments used against melanoma can compound the problem. In a large national analysis of hospitalized metastatic melanoma patients, those admitted with sepsis had in-hospital mortality nearly four times higher than those admitted without sepsis. The prevalence of sepsis among hospitalized melanoma patients increased over the study period, pointing to a growing burden of infection-related complications.19Journal of Clinical Oncology. Hospitalization patterns in metastatic melanoma patients with and without sepsis Infection was also the third most common recorded cause of death among advanced melanoma patients in the immunotherapy era, behind progressive wasting and respiratory failure.18PubMed Central. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
The reasons are multiple. The cancer itself diverts immune resources. Chemotherapy and targeted drugs suppress white blood cells. Even the checkpoint inhibitors that have revolutionized melanoma treatment work by unleashing the immune system against the tumor, but they can also trigger autoimmune side effects that require immunosuppressive drugs, creating windows of vulnerability to infection. Malnutrition from cachexia makes matters worse. Together, these factors mean that an otherwise routine urinary tract infection or pneumonia can escalate into organ failure and death.
How Melanoma Prepares Distant Organs Before Arriving
One of the more unsettling findings in melanoma biology is that tumors appear to prepare distant organs for colonization before any cancer cell arrives. The primary tumor releases tiny packages called exosomes into the bloodstream. These exosomes carry molecular cargo that alters the local environment at distant sites, promoting inflammation, blood vessel growth, and changes in the tissue structure that make it more hospitable to incoming tumor cells.20PubMed Central. Effects of exosomes on pre-metastatic niche formation in tumors
Intriguingly, this process is not identical across all melanoma types. Exosomes from non-metastatic melanoma cells were found to stimulate an immune patrolling response in the lungs, expanding a population of monocytes that actually help fight off incoming cancer cells. Exosomes from metastatic melanoma cells did not trigger this protective response, suggesting that the molecular cargo shifts as the cancer becomes more aggressive, switching from inadvertently alerting the immune system to evading it.21Nature Communications. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche This kind of research is still relatively early-stage, but it helps explain why melanoma has such a wide reach and why catching it before it becomes deeply invasive is so critical.
How Immunotherapy Has Changed the Pattern of Death
The introduction of checkpoint inhibitors in the 2010s dramatically improved survival for many patients with advanced melanoma, but it also shifted how and why patients die. In the pre-immunotherapy era, the autopsy literature consistently pointed to respiratory failure and brain complications as the top killers. In the immunotherapy era, the leading recorded cause of death has become progressive failure to thrive, followed by respiratory failure and infection.18PubMed Central. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era The vast majority of patients still die from melanoma-specific causes rather than unrelated conditions.
Immunotherapy has also introduced a distinction that matters for prognosis. Patients whose tumors respond to immunotherapy but later progress in the same established deposits tend to do far better than patients who develop entirely new metastases. One study found that patients who progressed in existing tumors after local therapy had a five-year disease-specific survival around 93%, compared to roughly 31% for those who developed new lesions.22Journal for ImmunoTherapy of Cancer. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma This suggests that the biology of how melanoma kills is not monolithic. The disease can be controlled in one pattern of failure but remain aggressive in another, and understanding which pattern a patient fits matters enormously for treatment decisions.
Uveal Melanoma and the Liver
Not all melanomas start on the skin. Uveal melanoma arises in the eye and follows a strikingly different metastatic playbook. While skin melanoma spreads to a wide range of organs, uveal melanoma overwhelmingly targets the liver. Roughly 90% of patients with metastatic uveal melanoma have liver involvement, with the lungs, bones, and soft tissues affected at much lower rates. Distant metastases develop in about a quarter to a third of patients within five years, and once metastases appear, the median overall survival is about one year, with a two-year survival rate of only around 8%.23PubMed Central. Management of liver metastases from uveal melanoma
The reason for this liver tropism is not fully understood, but it likely involves the unique vascular drainage of the eye and receptor-ligand interactions between uveal melanoma cells and liver tissue. The practical consequence is that uveal melanoma patients face a distinct set of risks from cutaneous melanoma patients: liver failure rather than brain hemorrhage tends to be the terminal event, and the immunotherapy drugs that have transformed skin melanoma outcomes have been far less effective against uveal melanoma. New treatments, including a bispecific T-cell engager approved in recent years, have begun to change that picture, but the prognosis for metastatic uveal melanoma remains grim.
Why Melanoma Can Switch Between Growing and Invading
At a cellular level, melanoma has an unusual ability to toggle between two states: one geared toward rapid growth and one geared toward invasion and migration. Researchers have described this as phenotype switching, a process in which melanoma cells change their gene expression profiles, shifting from a proliferative mode that builds up tumor mass to an invasive mode that allows cells to detach, enter the bloodstream, and colonize distant sites.24PubMed Central. Phenotype switching in melanoma: implications for progression and therapy This is loosely analogous to a process well-studied in other cancers, where epithelial cells take on features of more mobile cell types.
Phenotype switching matters for mortality because it means that a melanoma tumor is not a static mass. Different subpopulations of cells within the same tumor can be doing different things: some growing locally, others preparing to leave. This cellular flexibility also appears to play a role in resistance to targeted therapies. Drugs that block a key growth-driving mutation called BRAF can initially shrink melanoma dramatically, but the cancer can adapt by switching phenotypes, reactivating growth through alternative pathways. When resistance develops, the disease often rebounds with increased metastatic potential, and it is this rebound, not the original tumor, that tends to be fatal.